

Name: _____
Last Name First Name

Student Number: Answer Key

⊗⊗ [Some answers could have used different approaches]

PHARMACY 324
PHARMACOKINETICS
Term #1 EXAM
December 8, 2003

[Examination time is 3 hours]

This Examination has 17 pages.

PLEASE DO NOT DISASSEMBLE THIS EXAM!
PLEASE PLACE YOUR NAME ON EACH PAGE

Please read the ensuing examination questions and data provided carefully before attempting any calculations. **Show all your calculations.** All mathematical calculations should be written and organized in a logical, neat order. Double check all your answers where possible. Please express your final answers to three significant figures.

ASKING QUESTIONS IS REALLY NOT NECESSARY.

IF YOU ARE UNCERTAIN ABOUT SOMETHING,
MAKE ASSUMPTIONS WHEN ANSWERING A QUESTION.
IF SUCH ASSUMPTIONS ARE VALID THEY WILL BE CONSIDERED IN THE GRADING.

BUDGET YOUR TIME! WATCH THE VALUE OF THE QUESTIONS!

FACTS AND FIGURES: [NOTE UNDERLINED PARTS for THIS EXAM]

Cardiac output (CO) = 85 mL/min/kg total weight

Normal hematocrit (H) = 0.45 unless otherwise noted

Hepatic blood flow (Q_h) = 25% of cardiac output

Renal blood flow (Q_r) = 25% of cardiac output

Blood volume (L) = 8% of total weight

Body water (L) = 60% of total weight

BSA (m²) = (W^{0.425})(H^{0.725})(0.007184) [W = kg; H = cm]

% Fat = 90 - 2 (Height - Girth) [Height = inches; Girth = inches]

Lean body mass (LBM) = Total weight - Fat weight

Urine production rate = 0.0143 mL/min/kg total weight [for normal kidneys]


1 in = 2.54 cm

- NOTE:**
1. This exam is worth **35% of the final overall grade** in PHM 324. Please note however that the value of all questions totals 100 marks.
 2. The allotment of marks for each question is indicated beside each question.
 3. The available equations, as indicated in class, are found in the supplementary pages. Additional graph paper is found at the back of the exam.
 4. *This exam is designed to test your knowledge of pharmacokinetics and possibly even teach you about its use in problem situations. Some issues may be presented which were not specifically dealt with in lectures, but the context of the question should make their meaning clear.*

QUESTION 1: (26 marks; the marks are found beside each question)

In each of the following questions, some information is given. Answer the question based on the **DATA** or the **CHART**. Each **DATA** or **CHART** represents a new independent information source.

[4] a) **CHART:**




- [1] i) The half-life is 4 hr. $k = \frac{0.693}{4} = 0.17325 \text{ hr}^{-1}$
- [1] ii) The mean residence time is 5.77 hr. $MRT = \frac{1}{k}$
- [2] iii) Draw a line on the above CHART to show what would be expected if the dose increases by 100%.

[4] b) **DATA:** IV Dose = 200 mg
 $k = 0.1155 \text{ hr}^{-1}$
 C at 12 hr = 5 mg/L
 $V_1 = V_{ss}$

- [2] C^0 is 20 $\mu\text{g/mL}$. $C^0 = \frac{5}{e^{-k(12)}}$
- [1] Total AUC is 173 $(\mu\text{g/mL}) \cdot \text{hr}$. $AUC = \frac{20}{0.1155}$
- [1] Total clearance is 1.16 L/hr.

$$Cl_t = kV_1$$

[6] c) CHART: Dose for Patient A is 600 mg.



All of the following comparisons are against Patient A.

- [2] Draw a line on the above CHART for **Patient B** which has the same distribution space but twice the total body clearance. Identify your line for patient B.
- [2] Draw a line on the above CHART for **Patient C** which has the same clearance but one-half the distribution space. Identify your line for patient C.
- [2] Draw a line on the above CHART for **Patient D** which receives twice the dose, has one-half the distribution space and one-half the total clearance. Identify your line for patient D.

[6] d) DATA: Blood Data **

| | | |
|------------------|----------|---|
| $V_1 = V_{ss} =$ | 0.5 L/kg | $\dot{Q}_h \approx \dot{Q}_v = 1.275 \text{ L/kg/hr}$ $Cl_h = 0.2 (1.275)$ $Cl_r = 0.05 (1.275)$ $Cl_t = 0.25 (1.275)$ $fe = \frac{Cl_r}{Cl_t}$ |
| $CL_h = CL_m$ | | |
| $ER_{hepatic} =$ | 0.2 | |
| $ER_{renal} =$ | 0.05 | |


[3] The total body clearance is 0.319 L/kg/hr.

[2] $fe =$ 0.20

[1] Half-life = 1.09 hr

$k = \frac{Cl_t}{V_1} = \frac{0.31875}{0.5} = 0.6375$
 $t_{1/2} = \frac{0.693}{k}$

[6] e) CHART: Drug and one metabolite for **Patient A**; IV Dose of the drug is 600 mg.




[2] . The rate-limiting elimination constant for the metabolite is 0.173 hr⁻¹.

- [4] Draw line(s) on the above CHART for **Patient B** which has:
- the same distribution space for the DRUG
 - twice the total body clearance for the DRUG
 - has the same fm to the METABOLITE
 - the same inherent kinetic properties for the METABOLITE.

Identify any line(s) for patient B.

QUESTION 2: (7 marks; the marks are found beside each question)

The following scheme describes the fate of a drug (D) and its metabolites (M^1, M^2 etc.). All constants are in reciprocal hours. All concentrations in the body are in serum. The IV dose of the drug is 2 millimoles.



Drug (D)

$$f_e = \frac{0.05}{0.02 + 0.05 + 0.1 + 0.03} = \frac{0.05}{0.2} = 0.25$$

Excretion = (*) ↗

[5] Complete the following table based on the above scheme.


| Compound | Total Amount Excreted (millimoles) | Excretion Location |
|----------|------------------------------------|--------------------|
| D | $0.25(2) = 0.5$ | URINE |
| M^4 | 0 | Not excreted |
| M^1 | 0 | Not excreted |
| M^3 | $0.65(2) = 1.3$ | FECES |
| M^5 | $0.1(2) = 0.2$ | URINE |

[2] The terminal serum half-life of M^3 will be 231 hr.

$$\frac{0.693}{0.003} \leftarrow \text{Smallest constant}$$

QUESTION 3: (29 marks; the marks are found beside each question)

Decloxacin (DEC; molecular weight = 365) is a new antibiotic used to treat infections, including urinary tract pseudomonas infections. The drug is intended for both intravenous and oral administration. Mr. Martin (80 kg) was given an intravenous bolus dose (5mg/kg) of DEC. The following chart shows the serum concentrations versus time following the bolus dose.



Based on the above information, please answer the following questions:

- [5] a) The specific equation that best describes the DEC serum concentration versus time profile is:

$$C (\mu\text{g/mL}) = \frac{14.3e^{-1.5t} + 5.7e^{-0.1t}}{[\text{Coefficient(s) in } \mu\text{g/mL; constants in hr}^{-1} \text{ ; time in hours}]}$$

- [3] b) The total body clearance for DEC in Mr. Martin is 0.0752 L/hr/kg.

$$Cl_t = \frac{\text{Dose}}{AUC}$$

$$= (80 \text{ kg})(5 \text{ mg/kg}) = \frac{400 \text{ mg}}{66.5 (\text{mg/L}) \text{ hr}}$$

$$= 6.02 \text{ L/hr}$$

$$= 6.02 / 80 = 0.0752 \text{ L/hr/kg}$$

$$AUC = A/\alpha + B/\beta$$

$$= 14.3 / 1.5 + 5.7 / 0.1$$

$$= 66.5 (\text{mg/L}) \text{ hr}$$

- [3] c) The mean residence time for DEC in Mr. Martin is 8.67 hr.

$$MRT = \frac{AUMC}{AUC}$$

$$= \frac{576.4}{66.5}$$

$$= 8.67 \text{ hr}$$

$$AUMC = A/\alpha^2 + B/\beta^2$$

$$= 576.4 (\text{mg/L}) \text{ hr}^2$$

$$k_{21} = \frac{A\beta + B\alpha}{A+B} = 0.5 \text{ hr}^{-1}$$

$$k_{10} = \alpha B / k_{21} = 0.3 \text{ hr}^{-1}$$

$$k_{12} = (\alpha + \beta) - (k_{21} + k_{10}) = 0.8 \text{ hr}^{-1}$$

- [3] d) The steady state distribution space for DEC in Mr. Martin is 0.65 L/kg.

$$V_{SS} = V_1 \left(1 + k_{12}/k_{21} \right)$$

$$= 0.25 \left(1 + \frac{0.8}{0.5} \right)$$

$$= 0.65 \text{ L/kg}$$

$$\text{or via } AUMC \approx AUC$$

$$V_1 = \text{Dose} / A+B$$

$$= 0.25 \text{ L/kg}$$

- [2] e) The anticipated serum DEC concentration in Mr. Martin, 36 hours after the bolus dose, will be 0.156 $\mu\text{g/mL}$.

$$C = 14.3e^{-1.5(36)} + 5.7e^{-0.1(36)}$$

- [2] f) If "fe" for DEC in Mr. Martin is 0.25, the DEC renal clearance is 1.51 L/hr.

From b), $Cl_t = 6.02 \text{ L/hr}$

$$Cl_r = 0.25(Cl_t) = 1.51 \text{ L/hr}$$

- [4] g) If the urinary DEC concentration needed to inhibit pseudomonas growth in Mr. Martin is eleven (11) micrograms per mL, the 5 mg/kg IV bolus dose will continue to have an antibiotic effect for 25.1 hr.

① Urine formation rate = 0.0143 mL/min/kg
 $= 1.144 \text{ mL/min for } 80 \text{ kg}$
 $= 68.64 \text{ mL/hr}$

② Urine concentration = $11 \mu\text{g/mL}$

③ Urinary excretion rate = $11 (68.64) = 755.04 \mu\text{g/hr}$

④ Urinary excretion rate = (Serum conc)(Renal Clearance)
 $755.04 = 'x' (1.51 \text{ L/hr})$

$'x' = 500 \mu\text{g/L} \approx 0.5 \mu\text{g/mL}$


⑤ Figure of $C_{\text{vs } t}$ shows this must be in the β phase
 i.e. $0.5 = 5.7e^{-0.1(t)}$
 $t = 25.1 \text{ hr}$

- [3] h) At the time point calculated in question "g", 1.52 % of the DEC dose in Mr. Martin remains to be eliminated.

$$\text{At } 25.1 \text{ hr, AUC left} = \frac{C^{25.1}}{\beta} = \frac{0.5}{0.1} = 5 \text{ (}\mu\text{g mL) hr}$$

$$\therefore \% \text{ remaining} = \left(\frac{\text{AUC}_{25.1}^{\infty}}{\text{AUC}_0^{\infty}} \right) 100 = \frac{(5) 100}{66.5} = 1.52\%$$

- [4] i) The following serum DEC concentration profile was observed when a 600 mg oral dose of DEC was given to Mr. Martin on a separate occasion. In the space below the figure, describe any special pharmacokinetic characteristics of this oral dose.



Special features: (600 mg oral dose)

- ① The product exhibits a delay in absorption (time lag) of about 2 hrs.
- ② The terminal constant is about 0.043 hr^{-1} . This is smaller than α or β . Therefore, it appears absorption is rate-limiting the elimination process ($k_a \approx 0.043 \text{ hr}^{-1}$).
- ③ The above (#2) explains why a 2-cpt drug (DEC) shows 1-compartment characteristics in oral administration of the 600mg product.

QUESTION 4: (20 marks; 2.5 marks each)

Prezic™ is a newly marketed antidepressant drug which is eliminated by hepatic metabolism and renal excretion. The following plasma and urine data was obtained following the administration of a **10 mg IV dose** to a 68 kg male subject (45 years old).

PLASMA DATA:

| Time | Plasma Concentration (µg/L) Prezic™ |
|------|--|
| 0 | 54.3 |
| 3 | 27.15 |
| 6 | 13.6 |
| 12 | 3.4 |
| 24 | 0.42 |

Trapezoid AUC

$$AUC_0^{24} = 257.2 (\mu\text{g/L})\text{hr}$$

$$k = 0.231 \text{ hr}^{-1}$$

$$t_{1/2} = 3 \text{ hr}$$

$$AUC_{24}^{\infty} = \frac{0.42}{0.231} = 1.82$$

URINE DATA:

| Urine Collection Period | Amount Prezic™ in urine (mg) |
|-------------------------|------------------------------|
| 0-6 hr | 0.489 |
| 6-12 hr | 0.122 |
| 12-24 hr | 0.031 |

$$AUC_0^{\infty} = 257.2 + 1.82 = 259.0 (\mu\text{g/L})\text{hr}$$

$$Ae^{24} = 0.642 \text{ mg} = 642 \mu\text{g}$$

Part 1: Assuming a liver plasma flow rate of 825 ml/min, please calculate the following for Prezic™. Please show all work, whether calculations or figures to explain your answers. Page 14 offers graph paper and additional space, if this is needed.

a) $CL_R = \underline{41.6} \text{ ml/min.}$

$$CL_R = Ae^{24} / AUC_0^{24} = \frac{642 \mu\text{g}}{257.2 (\mu\text{g/L})\text{hr}} = 2.496 \text{ L/hr}$$

b) $CL_H = \underline{36.1} \text{ L/hr.}$

$$Cl_r = 2.496 \text{ L/hr}$$

$$Cl_t = \frac{\text{Dose}}{AUC} = \frac{10,000 \mu\text{g}}{259 \mu\text{g(L)hr}} = 38.6 \text{ L/hr}$$

$$\begin{aligned} Cl_r &= Cl_t - Cl_r \\ &= 38.6 - 2.5 \\ &= 36.1 \text{ L/hr} \end{aligned}$$

c) $t_{1/2} = \underline{3} \text{ hr.}$

via data on plot shown on p. 13.

d) Hepatic ER = 0.729.

$$\begin{aligned} ER &= Cl_r / Q_h; \quad Q_h = 825 \text{ mL/min} = 49.5 \text{ L/hr} \\ &= 36.1 / 49.5 = 0.729 \end{aligned}$$

e) $CL_{int} = \underline{133} \text{ L/hr.}$

$$\begin{aligned} Cl_{int} &= \frac{Q_h \times Cl_r}{Q_h - Cl_r} \\ &= \frac{49.5 \times 36.1}{49.5 - 36.1} \\ &= 133.3 \text{ L/hr} \end{aligned}$$

Part 2: Meals cause a reduction in hepatic plasma flow to approximately 650 ml/min. Estimate the following parameters if Prezic™ is taken with a meal. Assume that neither renal clearance nor intrinsic clearance is affected.

f) $CL_H = \underline{30.2} \text{ L/hr.}$

new $\dot{Q}_h = 650 \text{ mL/min}$
 $= 39 \text{ L/hr}$

$$Cl_h = \frac{\dot{Q}_h \times Cl_{int}}{Cl_{int} + \dot{Q}_h} = \frac{39 \times 133.3}{133.3 + 39} = 30.17 \text{ L/hr}$$

g) $t_{1/2} = \underline{3.92} \text{ hr.}$


$$V = \frac{\text{Dose}}{C_0} = \frac{10,000 \mu\text{g}}{54.3 \mu\text{g/L}} = 184.2 \text{ L}$$

new $Cl_t = Cl_r + Cl_h$
 $= 2.496 + 30.17$
 $= 32.67 \text{ L/hr}$


$$k = \frac{Cl_t}{V} = \frac{32.67}{184.2} = 0.177 \text{ hr}^{-1}$$

$$t_{1/2} = \frac{0.693}{0.177} = 3.92 \text{ hr}$$

Part 3: On the graph below, draw a representative line showing the anticipated change in plasma concentration versus time curve when liver blood flow is reduced (exact numbers not required).



Name: _____
Last Name First Name



QUESTION 5: (18 marks; the marks are found beside each question)

Offryth (OF) is an antiarrhythmic agent that has been tested in 12 healthy volunteers whose average total weight was 76 kg. Three doses were given randomly on separate occasions. Whole blood was analyzed.

The following average information was obtained after a 200 mg intravenous bolus dose:

| Parameter | Units | Values |
|---------------------------------------|-------------------------------------|--------|
| $V_1 = V_{ss}$ | L/kg | 3.9 |
| Total AUC | ($\mu\text{g/L}$)*hr | 6750 |
| Total AUMC | ($\mu\text{g/L}$)*hr ² | 67500 |
| Total OF Renally Excreted to 24 hours | mg | 130 |

The following average information was obtained after a 400 mg standard capsule given orally:

| Parameter | Units | Values |
|--------------|------------------------|--------|
| C^{24} | $\mu\text{g/L}$ | 95.4 |
| AUC to 24 hr | ($\mu\text{g/L}$)*hr | 9560 |
| k_a | hr ⁻¹ | 0.8 |
| Lag time | hr | 0 |

The following average information was obtained after a 432 mg slow release oral tablet:

| Parameter | Units | Values |
|--------------|------------------------|--------|
| C^{24} | $\mu\text{g/L}$ | 90.0 |
| AUC to 24 hr | ($\mu\text{g/L}$)*hr | 9020 |
| k_a | hr ⁻¹ | 0.45 |
| Lag time | hr | 1 |

Please answer the next series of questions based on the above OF data.

- [4] a) The specific equation that best describes the blood OF concentration versus time profile following the IV dose is:

$$C (\mu\text{g/L}) = \frac{675 e^{-0.1 * t}}{[\text{Coefficient(s) in } \mu\text{g/L; constants in hr}^{-1} \text{ ; time in hours}]}$$

1-cpt. drug

$$MRT = \frac{1}{k} = \frac{AUMC}{AUC} = \frac{67500}{6750} = 10 \text{ hr} \quad ; \quad k = 0.1 \text{ hr}^{-1}$$

$$C^0 = \frac{\text{Dose}}{V_1} = \frac{200 \text{ mg}}{(3.9)(76 \text{ kg})} = 675 \mu\text{g/L}$$

[4] b) The absolute extent of absorption for the standard oral OF capsule is 77.9 %.

$$F = \frac{AUC_o}{AUC_{iv}} \cdot \frac{Dose_{iv}}{Dose_o}$$

$$= \frac{10514}{6750} \times \frac{200}{400}$$

$$= 0.779$$

$$\begin{aligned} AUC_o &= 9560 + \frac{C^{24}}{k} \\ &= 9560 + \frac{95.4}{0.1} \\ &= 10514 \end{aligned}$$

[3] c) Although not presented, the expected t_{max} for the slow release oral tablet is 5.3 hr.

$$\begin{aligned} t_{max} &= \frac{\ln(R_a/k)}{R_a - k} = \frac{\ln(0.45/0.1)}{0.45 - 0.1} \\ &= 4.30 \text{ hr} \end{aligned}$$

$$t_{lag} = 1 \text{ hr}$$

$$\begin{aligned} \text{Total expected } t_{max} &= 4.30 + 1 \\ &= 5.30 \text{ hr} \end{aligned}$$

[7] d) The anticipated total unchanged OF to be excreted into urine after the slow release oral tablet will be 210 mg.

ORAL Tablet

$$Ae^{\infty} = f_e \cdot F \cdot \text{Dose}$$

$$F = \frac{AUC_o}{AUC_{IV}} \cdot \frac{\text{Dose}_{IV}}{\text{Dose}_o}$$

$$AUC_o = 9020 + \frac{90}{0.1} = 9920$$

$$= \frac{9920}{6150} \times \frac{200}{432} = 0.68$$

for IV data:

$$Ae^{24} = 130 \text{ mg.}$$

$$Cl_r = \frac{Ae^{24}}{AUC_o^{24}} = \frac{130 \text{ mg}}{6137.7} = 21.18 \text{ L/hr}$$

$$AUC_o^{24} = AUC_o^{\infty} - AUC_{24}^{\infty} = 6150 - \frac{61.23^*}{0.1} = 6137.7$$

$$Cl_t = \frac{\text{Dose}_{IV}}{AUC_{IV}} = \frac{200,000 \text{ mg}}{6750 \text{ (mg/L)hr}} = 29.63 \text{ L/hr}$$

$$f_e = \frac{Cl_r}{Cl_t} = 0.715$$

$$* = \frac{C^{24}}{k}$$

$$\therefore Ae^{\infty} = (0.715)(0.68)(432) = \underline{210 \text{ mg}}$$